Idorsia's P2RY12 antagonist inhibits platelet aggregation within 15 minutes

Idorsia Ltd. (SIX:IDIA) said single subcutaneous injections of selatogrel (ACT-246475) inhibited platelet aggregation within 15 minutes with its maximum effect extending over 4-8 hours depending on the dose in a pair of Phase II trials to treat stable coronary artery disease (CAD) and acute myocardial infarction (MI), respectively. The company plans to meet with regulatory authorities to discuss Phase III testing of the purinergic receptor P2Y G protein-coupled 12 (P2RY12; P2Y12) antagonist...